ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts – OncLive
OncLive |
ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts
OncLive Phase I results of this study previously showed that treatment with the CAR T-cell product JCAR017 demonstrated a CR rate of 59% and an ORR of 86% for patients with relapsed/refractory DLBCL (NCT02631044). In the findings to be presented at this … |
